Study Summary
The purpose of this study is to test the safety and efficacy of AUTO3, a CAR T cell treatment targeting CD19 and CD22 in paediatric or young adult patients with relapsed or refractory B cell acute lymphoblastic leukaemia.
Want to learn more about this trial?
Request More InfoInterventions
AUTO3 (CD19/22 CAR T cellsBIOLOGICAL
Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with 1 to 5.0 x 10⁶/kg CD19/CD22 Chimeric Antigen Receptor (CAR) positive T cells as a single or split dose.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Great Ormond Street Hospital for Children NHS Foundation Trust | London | United Kingdom | |
| University College London Hospitals NHS Foundation Trust | London | United Kingdom | |
| Royal Manchester Children's Hospital | Manchester | United Kingdom |